SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Critical Therapeutics (CRTX)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates3/7/2006 11:00:42 AM
   of 31
 
Critical Therapeutics Announces Research on ZYFLO(R) Presented at 2006 AAAAI Annual Meeting
Monday March 6, 4:45 pm ET

LEXINGTON, Mass.--(BUSINESS WIRE)--March 6, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced that two scientific posters on ZYFLO® (zileuton tablets) were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2006 Annual Meeting in Miami Beach, Florida.

William E. Berger, M.D., of Southern California Research, Mission Viejo, California, and Robert A. Nathan, M.D., of Asthma and Allergy Associates in Colorado Springs, Colorado, were lead authors of the posters.

The data were generated from retrospective analyses of two pivotal, randomized, placebo-controlled, double-blind, parallel, multi-center studies of the safety and efficacy of zileuton in 966 asthmatics. Both posters contained data from 483 asthma patients stratified into two patient groups, those with baseline forced expiratory volume (FEV(1)), a measure of lung function, of greater than 60%- less than 80% (n=257) and those with FEV(1) of less than or equal to 60% (n=226). Lung function measurements were obtained from patients on 600 mg zileuton four times per day (the prescribed dose) compared with placebo.

Lung Function

Data in Dr. Berger's poster noted that both zileuton patient groups experienced improvement in trough FEV(1) and peak expiratory flow rate (PEFR) compared with placebo.

Rescue Medication Use

Data in Dr. Nathan's poster noted that both zileuton patient groups showed decreases in asthma symptoms compared with placebo. Both zileuton patient groups also demonstrated a reduced need for beta-agonists and corticosteroid rescue.

The AAAAI is the largest professional medical specialty organization in the United States representing allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic disease. The 2006 AAAAI Annual Meeting is being held March 3-7 in Miami Beach, Florida. Abstracts of the posters presented by Dr. Berger and Dr. Nathan are available by clicking on the "Annual Meeting Abstracts" link at aaaai.org.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext